News & Updates

Show Multimedia Only

COVID-19 vaccine improves survival outcomes in cancer patients on ICI therapy

Vaccination against COVID-19 provides survival benefits to cancer patients receiving immune checkpoint inhibitors (ICIs), as shown in a recent study.

COVID-19 vaccine improves survival outcomes in cancer patients on ICI therapy

12 hours ago

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

18 hours ago

In the treatment of patients with resected non–small cell lung cancer (NSCLC) without sensitizing EGFR and ALK alterations, adjuvant nivolumab does not appear to yield improvements in disease-free survival (DFS) when given after planned adjuvant chemotherapy and/or radiotherapy, according to a phase 3 study.

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

18 hours ago

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

15 Jun 2026

A recent study has found procalcitonin to be a sensitive and specific serum biomarker for fibrolamellar carcinoma (FLC), making it a potential target for diagnosis and monitoring of treatment response.

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

15 Jun 2026

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

15 Jun 2026

An updated analysis of the IMbrave050 study reveals no sustained benefit on recurrence-free survival (RFS) among patients with high-risk hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. Moreover, data on overall survival (OS) remains incomplete.

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

15 Jun 2026

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026 by

In the treatment of patients with unresectable embolization-eligible hepatocellular carcinoma (eeHCC), combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen with or without lenvatinib substantially increases progression-free survival (PFS), as shown in the global phase 3 EMERALD-3 study.

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

12 Jun 2026 by

Immunotherapy directed at desmocollin-3 (DSC3) safely improves outcomes in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) expressing DSC3, reports a study presented at ASCO 2026.

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

12 Jun 2026

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

11 Jun 2026 by

In the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in China, the combination of ivonescimab plus chemotherapy significantly improves overall survival (OS) compared with tislelizumab plus chemotherapy, according to the phase III HARMONi-6 trial.

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

11 Jun 2026

Scoring system predicts postoperative complication in IPF patients with NSCLC

11 Jun 2026

A novel scoring system has shown its capacity in predicting postoperative pulmonary complications in patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF), reports a study.

Scoring system predicts postoperative complication in IPF patients with NSCLC

11 Jun 2026

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

11 Jun 2026 by

Adding low-dose pembrolizumab to chemotherapy results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with advanced non-small cell lung cancer (NSCLC), as shown in a phase 3 trial presented at ASCO 2026.

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

11 Jun 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

COVID-19 vaccine improves survival outcomes in cancer patients on ICI therapy

COVID-19 vaccine improves survival outcomes in cancer patients on ICI therapy

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

Original New Drug Application Approvals by US FDA (1-15 May 2026)

Original New Drug Application Approvals by US FDA (1-15 May 2026)

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

Scoring system predicts postoperative complication in IPF patients with NSCLC

Scoring system predicts postoperative complication in IPF patients with NSCLC

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC